A Look into The Future of Biotechnology. BIOTECH100 - CLASS A STOCK INDEX. 100 SMALL BIOTECHNOLOGY STOCKS WITH EMPHASIS IN DEVELOPMENT OF SMALL MOLECULE DRUGS THAT HAVE ONE OR MORE PRODUCTS CURRENTLY IN PHASE II OR PHASE III. BIOTECH100 - CLASS B STOCK INDEX. DRUGS IN CLINICAL TRIALS FOR THE BIOTECH100 INDEX.

Friday, October 14, 2011. I love the how the PR people put spins on data. Health care giant Johnson and Johnson likely will discuss its pipeline, recent drug approvals and several important deals when it reports its third-quarter results before the stock market opens Tuesday. The company may OR NOT! Give updates on several pending deals.

Quinta-feira, 19 de maio de 2011.

Thursday, December 13, 2007. The development of mechanical and bio-synthetic devices has sprung new hope for those with impaired vision. However, current artificial vision technology can only aid those who have lost their vision later in life and still have a fairly intact visual system. Unfortunately, to date, no visual prosthesis has been able to restore vision to people who are born blind due to structural defects in the eye or visual cortex. Over the past three decades, various technologies have been.

The joint BioTech 2008 and the 4. The further potential of recombinant yeasts, in particular Pichia pastoris, Hansenula polymorpha, Yarrowia lipolytica,. Molecular biology tools for pathway engineering and custom-designed glycosylation.